Retina Institute Japan and Dainippon Sumitomo Pharma Co., Ltd. Form a Capital Alliance Towards the Development of Nobel Prize Winning iPS Cell Technology
3/29/2013 9:07:02 AM
More...
|
Edison Pharmaceuticals, Inc. Signs Licensing Agreement With Dainippon Sumitomo Pharma Co., Ltd. for Up to $545 Million
3/28/2013 7:35:41 AM
More...
|
Dainippon Sumitomo Pharma Co., Ltd. Sumitomo Seeks SFDA Approval for Cancer Drug
9/4/2012 10:25:58 AM
More...
|
Dainippon Sumitomo Pharma Co., Ltd. Reports that Latuda® (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression
5/7/2012 7:34:12 AM
More...
|
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C’s Life Sciences Practice Represents Boston Biomedical in its Agreement with Dainippon Sumitomo Pharma Co., Ltd. to be Acquired for up to $2.63 Billion
3/5/2012 6:04:27 AM
More...
|
Dainippon Sumitomo Pharma Co., Ltd. Bags Boston Biomedical for $2.6 Billion
2/29/2012 7:28:33 AM
More...
|
Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
4/7/2011 8:06:38 AM
More...
|
Dainippon Sumitomo Pharma Co., Ltd. and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease; Dainippon Pays Intercept $15 Million and up to $300 Million
3/30/2011 7:00:17 AM
More...
|
Codexis Pharmaceuticals Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma Co., Ltd.
1/25/2011 6:31:56 AM
More...
|
Dainippon Sumitomo Pharma Co., Ltd.'s Sunovion Pharmaceuticals Inc. (SEPR)'s Schizophrenia Pill, Latuda Gets FDA Nod
10/29/2010 6:53:14 AM
More...
|
|